Yong-Fu Xiao
Cardiovascular and Metabolic Diseases, Crown Bioscience, Inc.,
6 Beijing West Road, Taicang, Jiangsu Province, The People’s Republic of China, (Adjunct Professor, Department of Pharmacology, Physiology & Neuroscience, Rutgers University-New Jersey Medical School, Newark, NJ)
Tanzania
Research Article
Dysglycemia and Dyslipidemia Models in Nonhuman Primates: Part III. Type I or II Diabetogenic Effects of Streptozocin
Author(s): Yongqiang Liu, Jiajun Gao, Xiaoli Wang, Yixin Jim Wang and Yong-Fu XiaoYongqiang Liu, Jiajun Gao, Xiaoli Wang, Yixin Jim Wang and Yong-Fu Xiao
Streptozocin (STZ), a naturally occurring glucosamine-nitrosourea compound, has been used for diabetogenic induction in animals for diabetic research due to its high toxicity to pancreatic beta cells. This study was to evaluate the diabetogenic effects of STZ by multiple low doses or by single high dose in normoglycemic Non-Human Primates (NHPs). Each monkey in the 1st group (n=6) was intravenously administered with 7.5 to 15 mg/kg STZ once every 2 to 4 weeks until successful induction of hyperglycemia or until the end of this 28-week study. In the 2nd group (n=7) each monkey was intravenously injected with 35 mg/kg STZ once only. Plasm glucose, insulin and lipid levels were monitored weekly during the study. The hyperglycemic responses to STZ were more severe in the NHPs treated with the single high dose. Among them one animal died on the 2nd day after STZ dosing. Compared with STZ m.. View More»
